Fresh from the biotech pipeline: FDA approvals settle in 2024, but what next?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

6 citing papers in PubMed.

1. Sequence and structural determinants of efficacious de novo chimaeric antigen receptors.Nature biomedical engineering · 2026
   Article
2. HaloTag-Based FACS-Compatible Assay for Intracellular Haloalkane Detection with a Potential Application to Halogenase Screening.Analytical chemistry · 2026
   Article
3. Conformational Preferences for N-Glycans at the Surface of CEACAM1-Ig1.ACS chemical biology · 2026
   Article
4. Sequence and structural determinants of efficaciousbioRxiv : the preprint server for biology · 2025
   Article
5. Biomimetic Cell Membrane-Coated Scaffolds for Enhanced Tissue Regeneration.Advanced materials (Deerfield Beach, Fla.) · 2025
   Review
6. Pharmaceutical perspectives on oligonucleotide therapeutics and delivery systems.Pharmacological reviews · 2025
   Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.